ESR1 and neoplasm: These processes can fuel anti-tumor immunity, although the dynamic and complex responses to RT also include recruited MDSCs and Tregs that can antagonize this effect [11–13, 17], and RT alone was not sufficient to sensitize advanced clinical ER+ breast cancers to immune checkpoint inhibition with α-PD-1 [18], as mimicked in our experimental model.